Obesity, diabetes and VLCDs

Bennett, Peggy D.

doi:10.1177/14746514040040050701

Cited by 3 publications

(3 citation statements)

References 7 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nutritionally balanced low calorie and VLCDs are available as meal replacement drinks, soups and bars, and a range of high protein/low carbohydrate, high fibre, defined preparation/cooking procedures, food group exclusion diets – all of which are designed to reduce energy intake – are actively promoted by the media. 27,28 Rapid weight loss has inherent risks and fad diets, while difficult to maintain, may also result in undesired metabolic sequelae and malnutrition.…”

Section: Fad Dietsmentioning

confidence: 99%

The hypocaloric diet in type 2 diabetes - déjà vu

Day

Bailey

2012

Diabetes & Vascular Disease

View full text Add to dashboard Cite

Dietary modification is considered a cornerstone in the management of diabetes superimposed upon which are pharmacological therapies as required. The value of hypocaloric diets in reducing and eliminating glycosuria was extolled in the pre-insulin era. A common feature of the nutrient balance of these diets was restriction in the availability of carbohydrate. Herein we review the use of diet as therapy in the past and discuss the rationale for hypocaloric dietary management of type 2 diabetes in the 21st century, drawing comparisons with bariatric surgery and considering why weight loss is particularly difficult for overweight and obese individuals with type 2 diabetes.

show abstract

Section: Fad Dietsmentioning

confidence: 99%

The hypocaloric diet in type 2 diabetes - déjà vu

Day

Bailey

2012

Diabetes & Vascular Disease

View full text Add to dashboard Cite

show abstract

“…Short-term use of nutritionally complete commercially available (very) low calorie diets has benefited people with diabetes when supported by education programmes. 2 Initial weight loss has been encouraging with some fad diets eg the Atkins and the South Beach diets, but these diets are difficult to maintain and there are safety issues regarding their short-and long-term use -especially in people with diabetes. 3 The types of macronutrients consumed can have a considerable impact on glycaemic control and energy metabolism.…”

Section: Which Weight Loss Diet?mentioning

confidence: 99%

Editorial: Which weight loss diet?

Day

Bailey²

2009

Diabetes & Vascular Disease

View full text Add to dashboard Cite

PRESENTATION: 10 mg Tablet containing 10 mg of ezetimibe. USES: As adjunctive therapy to diet in: Primary hypercholesterolaemia: For co-administration with an HMG CoA reductase inhibitor (statin) for patients with primary (heterozygous familial and non-familial) hypercholesterolaemia not appropriately controlled with a statin alone. Monotherapy: For use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia in whom a statin is considered inappropriate or is not tolerated. Homozygous Familial Hypercholesterolaemia (HoFH): For co-administration with a statin, for use in patients with HoFH. Patients may also receive adjunctive treatments (e.g. LDL apheresis). Homozygous sitosterolaemia (phytosterolaemia): For use in patients with homozygous familial sitosterolaemia. Studies to demonstrate the efficacy of 'Ezetrol' in the prevention of complications of atherosclerosis have not yet been completed. DOSAGE AND ADMINISTRATION: For oral administration: Put patients on an appropriate lipid lowering diet and continue during treatment. Recommended dose is one 'Ezetrol' 10 mg tablet daily, administered at any time of the day, with or without food. When added to a statin, either continue with the indicated usual initial dose of that particular statin or the already established higher statin dose. Consult the statin dosage instructions. Co-administration with bile acid sequestrants: Dosing should occur either ≥2 hours before or ≥4 hours after administration of a bile acid sequestrant. Use in paediatric patients: Children <10 years: Not recommended as no clinical data are available. Use in hepatic impairment: No dosage adjustment is required with mild hepatic insufficiency (Child Pugh score 5 to 6). Not recommended in patients with moderate (Child Pugh score 7 to 9) or severe (Child Pugh score >9) liver dysfunction. CONTRA-INDICATIONS: Hypersensitivity to any component. When co-administered with a statin, refer to the statin SPC. 'Ezetrol' co-administered with a statin during pregnancy and lactation. 'Ezetrol' co-administered with a statin in patients with active liver disease or unexplained persistent elevations in serum transaminases. PRECAUTIONS: Liver enzymes: When co-administered with a statin, perform liver function tests at initiation of therapy and according to the statin SPC. Skeletal muscle: In post-marketing experience with 'Ezetrol', myopathy and rhabdomyolysis have been reported. Most patients who developed rhabdomyolysis were taking a statin concomitantly with 'Ezetrol'. However, rhabdomyolysis has been reported very rarely with 'Ezetrol' monotherapy and very rarely with the addition of 'Ezetrol' to other agents known to be associated with increased risk of rhabdomyolysis. If myopathy is suspected based on muscle symptoms or is confirmed by a creatinine phosphokinase (CPK) level >10 times the ULN, immediately discontinue 'Ezetrol', any statin, and any of these other agents. Advise all patients starting therapy with 'Ezetrol' of the risk of myopathy and to report promptly any unexpla...

show abstract

“…Whilec ollaborative approaches to care aref ound more commonlyi nc ommunity services( Connor,R ainer;e ta l2 007), other examples include clinicians workingw ithp articularp opulation groups such as the indigenousp opulations (de Crespigny,E mden et al 2004)a nd obesei ndividuals ( Bennett 2004).I nr eality, however, clinicians'r eportt hat collaboration, while ideal,i sd ifficult and is seldom achieved (McCauley-Elsom2009).…”

Section: Introductionmentioning

confidence: 99%